A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease

Summary

The purpose of this study is to evaluate the safety and efficacy of five fixed dosage levels of FK962 or placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease. Patient visits are every six weeks with limited efficacy measurements at week 6 and 18.

Timeline

Start

2004-07

Primary completion

—

Completion

2006-09

Drugs

Indications